ライフサイエンスコーパス: pulmonary valve

1 the animals with stents placed distal to the pulmonary valve.

2 lmonic stenosis, pulmonic atresia and absent pulmonary valve.

3 identified as that due to the absence of the pulmonary valve.

4 n the endograft at the level of the original pulmonary valve.

5 re piglets (n = 14) were used for PHT of the pulmonary valve.

6 th or without the need of replacement of the pulmonary valve.

7 transcatheter placement of stents across the pulmonary valve.

8 n's syndrome patients or those with unusable pulmonary valves.

9 part of the heart containing the aortic and pulmonary valves.

10 tissue and isolated interstitial cells, than pulmonary valves.

11 rs frequently in aortic valves but rarely in pulmonary valves.

12 ctin-positive VICs in neonatal aortic versus pulmonary valves.

13 s, we isolated clonal populations from human pulmonary valves.

14 ineered valves reminiscent of that in native pulmonary valves.

15 urgitation severity was discordant for seven pulmonary valves, 22 mitral valves, and 21 tricuspid val

16 e mitral and aortic but not the tricuspid or pulmonary valves, accompanied by inflammatory cell infil

17 nary atresia with ventricular septal defect, pulmonary valve agenesis, aortopulmonary window, and dou

18 patient with tetralogy of Fallot with absent pulmonary valve and extra-cardiac phenotypes.

19 RVCO calculated from blood flow through the pulmonary valve and from QDA and QP was good (r = .97, P

20 Nitinol stents were placed in the pulmonary valve and main pulmonary artery in five pigs b

21 ly resect the right posterior leaflet of the pulmonary valve and replace it with an engineered valve

22 such as transcatheter perforation of atretic pulmonary valves and endovascular stenting for coarctati

23 with dysfunctional native or patch-repaired pulmonary valves and RVOT enlargement.

24 l technique, transcatheter implantation of a pulmonary valve, and outlines how real-time MRI in the n

25 rvention for failing implanted bioprosthetic pulmonary valves, and considers a new approach to determ

26 Blood flows at the aortic and pulmonary valve annuli (LVCO and RVCO, respectively), ri

27 ons had a significantly higher occurrence of pulmonary valve atresia (P = 0.001) compared with cases

28 between air pollution and CHDs (specifically pulmonary valve atresia/stenosis, tetralogy of Fallot [T

29 s and diminutive pulmonary arteries, initial pulmonary valve balloon dilation increases the annulus Z

30 for 10 such patients undergoing preoperative pulmonary valve balloon dilation, among other transcathe

31 th moderate neo-AI at discharge had abnormal pulmonary valves before surgery.

32 atients with RVOT conduits and bioprosthetic pulmonary valves by providing sustained symptomatic and

33 asal bulging and LV conicity (p < 0.05), and pulmonary valve dilation (p < 0.01).

34 : Ebstein's anomaly, the failing Fontan, and pulmonary valve disease.

35 Fetal aortic and pulmonary valve; ductus arteriosus (DA); and right (RPA)

36 subjects with RVOT conduit or bioprosthetic pulmonary valve dysfunction were enrolled.

37 osus, 2 with tetralogy of Fallot, and 1 with pulmonary valve dysplasia.

38 peptide inhibitor reduced VEGF-induced human pulmonary valve endothelial cell proliferation, indicati

39 GF stimulates NFATc1 nuclear import in human pulmonary valve endothelial cells by a calcineurin-depen

40 monstrate that activation of NFATc1 in human pulmonary valve endothelial cells is specific to vascula

41 ted and translocated to the nucleus in human pulmonary valve endothelial cells to gain a better under

42 t is an emerging therapy intended to restore pulmonary valve function in patients with right ventricu

43 Preservation or restoration of pulmonary valve function may thus reduce the risk of sud

44 In HLHS, the pulmonary valve functions as the neo-aortic valve.

45 At most recent follow-up, the maximum pulmonary valve gradient by echocardiogram remained sign

46 Transcatheter aortic and pulmonary valves have been used to treat stenosis or reg

47 of the novel Medtronic Harmony transcatheter pulmonary valve (hTPV) and to assess its effect on pulmo

48 ressure gradient acutely after transcatheter pulmonary valve implantation (39 versus 10 mm Hg; P<0.00

49 d pulmonary regurgitation (PR), percutaneous pulmonary valve implantation (PPVI) aims to preserve RV

50 Percutaneous pulmonary valve implantation (PPVI) can treat this condi

51 Percutaneous pulmonary valve implantation (PPVI) has become an import

52 Percutaneous pulmonary valve implantation (PPVI) has been developed a

53 Percutaneous pulmonary valve implantation (PPVI) is a safe, less inva

54 iological effects of BMS versus percutaneous pulmonary valve implantation (PPVI) using an x-ray/magne

55 within pediatric cardiology is percutaneous pulmonary valve implantation (PPVI).

56 of congenital heart disease had percutaneous pulmonary valve implantation (PPVI).

57 Transcatheter pulmonary valve implantation (TPVI) is indicated to trea

58 heart disease underwent Melody percutaneous pulmonary valve implantation at our institution.

59 e Melody device (Medtronic) for percutaneous pulmonary valve implantation experience stent fractures

60 f patients who underwent Melody percutaneous pulmonary valve implantation experienced subsequent BSI,

61 The primary percutaneous pulmonary valve implantation indication was right ventri

62 Percutaneous pulmonary valve implantation using a stent-based biopros

63 Transcatheter pulmonary valve implantation using the Melody valve has

64 Transcatheter pulmonary valve implantation using the Melody valve with

65 outcomes of patients in whom a percutaneous pulmonary valve implantation was performed using the fol

66 All patients who benefit from percutaneous pulmonary valve implantation with a folded Melody valve

67 w the combined experience with transcatheter pulmonary valve implantation within BPVs from 8 centers

68 lacement of >/=1 stents before transcatheter pulmonary valve implantation.

69 ed follow-up for patients after percutaneous pulmonary valve implantation.

70 ay be associated with BSI after percutaneous pulmonary valve implantation.

71 scular nitinol stents were placed across the pulmonary valve in 6 young pigs to induce pulmonary regu

72 valve was affected in all 8 patients (73%), pulmonary valve in 7 (64%), and left sided valves in 4 (

73 The stent was placed distal to the pulmonary valve in four animals and across the pulmonary

74 lmonary valve in four animals and across the pulmonary valve in one animal.

75 rated that TVR with the Melody transcatheter pulmonary valve in properly selected patients is safe, e

76 ment patch, but this causes issues including pulmonary valve insufficiency and progressive right vent

77 aortic valve interstitial cells (AVICs) and pulmonary valve interstitial cells (PVICs) differ in exp

78 is, with selective absence of the aortic and pulmonary valves, leading to death in utero from congest

79 lymer construct was implanted to replace one pulmonary valve leaflet in the same juvenile animal from

80 Tc1 was detected in the endothelium of human pulmonary valve leaflets by immunohistochemistry.

81 Human aortic and pulmonary valve leaflets from the same heart were collec

82 rm effectiveness of the Melody transcatheter pulmonary valve (Medtronic, Inc., Minneapolis, Minnesota

83 n the survival with the originally implanted pulmonary valve (Melody group, 80%; SPVR group, 73%; P=0

84 stheses, 36 mechanical), and 157 underwent a pulmonary valve operation.

85 he potential to guide stent placement in the pulmonary valve or artery and to evaluate flow volume wi

86 circulation due to severe stenosis involving pulmonary valves or arteries or due to pulmonary atresia

87 tetralogy of Fallot (cTOF) often results in pulmonary valve pathology and right ventricular (RV) dys

88 Transcatheter pulmonary valve placement is an emerging therapy for pul

89 124 patients; in the other 12, transcatheter pulmonary valve placement was not attempted because of t

90 has recently been treated with transcatheter pulmonary valve placement.

91 In all animals, the TEL persisted in the pulmonary valve position after 8 to 10 weeks, and all po

92 n of these autologous tissue leaflets in the pulmonary valve position in a lamb model.

93 ar nitinol stents in the pulmonary artery or pulmonary valve position.

94 n of these autologous tissue leaflets in the pulmonary valve position.

95 Anatomic abnormalities of the pulmonary valve preclude its use as an autograft.

96 cedures, 1,375 PDA procedures, 270 "typical" pulmonary valve procedures, 305 aortic valve procedures,

97 Off-label use of transcatheter aortic and pulmonary valve prostheses for tricuspid valve-in-valve

98 offending endograft with preservation of the pulmonary valve prosthesis.

99 were to determine the growth pattern of the pulmonary valve (PV) annulus and right heart structures

100 ates the contribution of infundibular versus pulmonary valve (PV) dysfunction on right ventricular (R

101 The pulmonary valve (PV) is of primary concern because of it

102 Percutaneous pulmonary valve (PV) replacement was successful in all p

103 We chose the pulmonary valve (PV) to study, due to its importance in

104 LVOTO was defined as pulmonary valve (PV) z-score < or =-2.0 or LVOT gradient

105 edictive scores for specific gestations were pulmonary valve (PV) z-score (<23 weeks), median TV z-sc

106 haracteristically affects tricuspid (TV) and pulmonary valves (PV), and TV replacement is helpful in

107 the rest had none/trace; 1 patient had mild pulmonary valve regurgitation and the remainder had none

108 was designed for treatment of postoperative pulmonary valve regurgitation in patients with repaired

109 radient (1 mixed lesion with moderate/severe pulmonary valve regurgitation).

110 lar end-diastolic dimensions and severity of pulmonary valve regurgitation.

111 -652) days, there were no deaths or need for pulmonary valve reintervention.

112 Indications for surgical pulmonary valve replacement (PVR) after repair of tetral

113 Pulmonary valve replacement (PVR) after repair of tetral

114 The timing of pulmonary valve replacement (PVR) for free pulmonary inc

115 Pulmonary valve replacement (PVR) in patients with repai

116 Because the real benefit of pulmonary valve replacement (PVR) in patients with repai

117 Current indications for pulmonary valve replacement (PVR) in repaired tetralogy

118 Pulmonary valve replacement (PVR) in repaired tetralogy

119 Although pulmonary valve replacement (PVR) is effective in reduci

120 The impact of pulmonary valve replacement (PVR) on major adverse clini

121 ts with repaired tetralogy of Fallot require pulmonary valve replacement (PVR), but the evaluation fo

122 Electrophysiological studies (EPS) before pulmonary valve replacement (PVR), the most common reint

123 TOF) or pulmonary stenosis (PS) referred for pulmonary valve replacement (PVR).

124 for Ebstein's anomaly, Fontan revision, and pulmonary valve replacement (PVR).

125 me of PPVI with the Melody valve to surgical pulmonary valve replacement (SPVR) are lacking.

126 Transcatheter pulmonary valve replacement (TPVR) has become a useful t

127 Transcatheter pulmonary valve replacement (TPVR) in patients with a co

128 Transcatheter pulmonary valve replacement (TPVR) is an established the

129 Transcatheter pulmonary valve replacement (TPVR) is associated with a

130 ed data focused on outcomes of transcatheter pulmonary valve replacement (TPVR) with either a Sapien

131 have been reported early after transcatheter pulmonary valve replacement (TPVR) with the Harmony valv

132 Follow-up of transcatheter pulmonary valve replacement (TPVR) with the Melody valve

133 Transcatheter pulmonary valve replacement (TPVR) with the self-expandi

134 impactful adverse events after transcatheter pulmonary valve replacement (TPVR), but there is limited

135 dable valves are effective for transcatheter pulmonary valve replacement but linked to higher transie

136 Percutaneous pulmonary valve replacement has recently opened new pers

137 tricuspid valve replacement in all patients, pulmonary valve replacement in 3 and valvectomy in 7, mi

138 y offer an alternative for standard surgical pulmonary valve replacement in dilated right ventricular

139 balloon-expandable valves for transcatheter pulmonary valve replacement in dysfunctional right ventr

140 V) offer a promising alternative to surgical pulmonary valve replacement in patients with a large pat

141 w tracts, permitting lower risk, nonsurgical pulmonary valve replacement in previously prohibitive an

142 Transcatheter pulmonary valve replacement is evolving, but to date, ex

143 cular dilation and dysfunction necessitating pulmonary valve replacement is uncommon in long-term fol

144 icant PR with RV dilation, optimal timing of pulmonary valve replacement remains uncertain, although

145 ongenital heart disease (CHD), transcatheter pulmonary valve replacement represents a transformative

146 Pulmonary valve replacement should be performed before t

147 rapies, including transcatheter and surgical pulmonary valve replacement strategies, as well as manag

148 Transcatheter pulmonary valve replacement using the Edwards SAPIEN tra

149 for 145 patients who underwent transcatheter pulmonary valve replacement with Edwards SAPIEN 3 (ES3)

150 ents in patients who underwent transcatheter pulmonary valve replacement with the Harmony TPV25 devic

151 Transcatheter pulmonary valve replacement with the Harmony valve is fe

152 e remodeling (QRS fragmentation and previous pulmonary valve replacement) (+2.7%; 95% confidence inte

153 0%), 0.9% (0.2%-1.6%), and 3.8% (0.0%-8.4%); pulmonary valve replacement, 0.4% (0.0%-0.8%), 1.3% (0.2

154 ctors and risk mitigating strategies such as pulmonary valve replacement, ablative strategies, and us

155 underwent mitral and tricuspid valve repair, pulmonary valve replacement, and a maze procedure (the l

156 al choices such as transcatheter or surgical pulmonary valve replacement, discusses criteria and opti

157 ps with symptoms, restrictive RV, RV EF<40%, pulmonary valve replacement, or QRS fragmentation.

158 erienced infective endocarditis; 11 required pulmonary valve replacement, with a lower incidence for

159 valuable tool to stratify cTOF patients for pulmonary valve replacement.

160 termining optimal timing and indications for pulmonary valve replacement.

161 d balloon-expandable valves in transcatheter pulmonary valve replacement.

162 effect on TR, as is often seen with surgical pulmonary valve replacement.

163 ncluding RVOT reconstruction, at the time of pulmonary valve replacement.

164 mean number of cardiovascular interventions, pulmonary valve replacements (PVRs), and cardiovascular

165 lves (TEHVs) was evaluated up to 24 weeks as pulmonary valve replacements (transapical access) in she

166 ry resistance, pulmonary arterial elastance, pulmonary valve resistance and systemic arterial elastan

167 oplasty is considered first-line therapy for pulmonary valve stenosis and generally results in succes

168 The most prominent cardiac defects in NS are pulmonary valve stenosis and hypertrophic cardiomyopathy

169 alvuloplasty for the treatment of aortic and pulmonary valve stenosis was first described nearly 40 y

170 r septal defects, atrial septal defects, and pulmonary valve stenosis) occurred in 2.0 per 1000 birth

171 graphic abnormalities, ocular hypertelorism, pulmonary valve stenosis, abnormal genitalia, retardatio

172 r septal defect, pulmonary artery anomalies, pulmonary valve stenosis, hydrocephalus) with trends in

173 gen dioxide and coarctation of the aorta and pulmonary valve stenosis.

174 The incidence of Melody transcatheter pulmonary valve stent fracture (3.4%) and infectious end

175 mined from points assigned for tricuspid and pulmonary valve structure and function.

176 mmon atrioventricular canal (n = 17), absent pulmonary valve syndrome (n = 24) and aortopulmonary win

177 8) of fetuses with TOF, excluding the absent pulmonary valve syndrome, survived.

178 the animal with the stent placed across the pulmonary valve, the pulmonary regurgitant fraction was

179 1.3% (0.2%-2.4%), and 8.0% (1.2%-14.8%); and pulmonary valve thrombosis, 0.4% (0.0%-0.9%), 0.7% (0.0%

180 rger valves (P = .009), and four experienced pulmonary valve thrombosis, including one who died and t

181 Initially employed to cross atretic pulmonary valves, tissue traversal has enabled transcava

182 imary outcome was freedom from transcatheter pulmonary valve (TPV) dysfunction (freedom from reoperat

183 In 2010, the Melody transcatheter pulmonary valve (TPV) received Food and Drug Administrat

184 Transcatheter pulmonary valve (TPV) replacement (TPVR) has become the

185 Transcatheter (percutaneous) pulmonary valve (TPV) replacement has emerged as a viabl

186 Transcatheter pulmonary valve (TPV) replacement is an emerging therapy

187 Melody Transcatheter Pulmonary Valve (TPV) replacement therapy represents an

188 Studies of transcatheter pulmonary valve (TPV) replacement with the Melody valve

189 The Melody transcatheter pulmonary valve (TPV) was approved for implantation in o

190 The Harmony transcatheter pulmonary valve (TPV) was designed for treatment of post

191 Self-expanding transcatheter pulmonary valves (TPV) offer a promising alternative to

192 factors for endocarditis, but transcatheter pulmonary valve type was not.

193 he aortic arch, dysgenesis of the aortic and pulmonary valves, ventricular septal defects, and other

194 y bypass, the right posterior leaflet of the pulmonary valve was completely resected and replaced wit

195 ore hemodynamic and 3D ultrasonic study, the pulmonary valve was excised from 6 sheep (31 to 59 kg) t

196 The pulmonary valve was first balloon dilated (mean balloon/

197 The pulmonary valve was replaced in 33 cases (59) and the tr

198 tflow tract (RVOT) conduits or bioprosthetic pulmonary valves, while preserving RV function and reduc

199 The CAM-based monocusp offered a competent pulmonary valve with regurgitation of 4.6 +/- 0.9% and a